Navigation Links
Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
Date:2/21/2013

CHAPEL HILL, N.C., Feb. 21, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that it will report fourth quarter and full year 2012 financial results and provide a business update after the close of U.S. financial markets on February 28, 2013. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EST, February 28, 2013.

The conference call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers. Please specify to the operator that you would like to join the "Cempra, Inc., Fourth Quarter and Full Year 2012 Financial Results Call, conference ID#: 12497222." The conference call will be webcast live under the investor relations section of Cempra's website at www.cempra.com, and will be archived there for 30 days following the call. Please visit Cempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are in advanced clinical development; solithromycin in Phase 3 for CABP and TAKSTA™ (CEM-102) in Phase 2 for prosthetic joint infections.  Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to use its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Investor and Media Contacts:
Robert E. Flamm , Ph.D.
Russo Partners, LLC
(212) 845-4226 
Robert.flamm@russopartnersllc.com

Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com


'/>"/>
SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
2. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
3. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
4. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
5. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
6. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
7. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
8. Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
9. Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
10. Tomorrows Outlook in Todays Market - Research Report on Toyota Motor Corporation, Honda Motor Co., Ltd., Yahoo! Inc., AOL, Inc. and Aegerion Pharmaceuticals, Inc.
11. Medical Equipment Suppliers in Good Health - Research Report on Bruker Corporation, Agilent Technologies Inc., General Electric Company, Becton, Dickinson and Co. and Thermo Fisher Scientific Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... BAUDETTE, Minn. , Jan. 17, 2017 /PRNewswire/ ... ) today announced the appointment of Karen Quinn ... January 17, 2017.  Karen ... years of leadership experience in Global Regulatory Affairs, ... biologically-derived active pharmaceutical ingredients.  Dr. Quinn worked most ...
(Date:1/17/2017)... pioneer in no-touch UV disinfection has now been validated by ... for "total room ultraviolet disinfection," was the device of choice ... study which was recently published in The Lancet ... transmission of four major superbugs by a cumulative 30 percent. ... we have been committed to innovation and the science behind ...
(Date:1/16/2017)... Research and Markets has announced the addition ... to their offering. ... Global multiple myeloma drugs market to grow at a CAGR ... covers the present scenario and the growth prospects of the global ... the report considers the revenue generated from the sales of branded ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... , ... California Southern University has named Dr. Steven Beazley University President. ... as a core faculty member, teaching master’s and doctoral courses in the university’s School ... University, where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also ...
(Date:1/16/2017)... ... , ... With the Grand Opening Event planned for February 3, 2017, the ... and the general public. Built in five months by Centerpoint, the 60,000 square foot ... or pickleball courts. The space is also suitable for indoor soccer and football training. ...
(Date:1/16/2017)... New York (PRWEB) , ... January 16, 2017 ... ... SightMD today announced the addition of Victor Giamos, MD to their ... of SightMD and Managing Partner at North Shore Eye Care, a division of ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... partnership with an innovator in the wheelchair accessibility industry, BraunAbility . Incentive ... salespeople to sell wheelchair accessible vehicles. With this new incentive plan, BraunAbility plans ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic surgeon ... , the official journal of The American Society for Aesthetic Plastic Surgery, in ... procedure is designed to correct drooping, retracted lower eyelids, which usually result from ...
Breaking Medicine News(10 mins):